Drug reference

Lamivudine with tenofovir disoproxil

BNF 80 (2020–2021)

Source: BNF 80 (2020–2021)
PDF pages: 712

Review source pages for extracted sections and age labels. BNF dose snippets show only their first line.

Overview

Indications And Dose

HIV-1 infection in combination with other antiretroviral drugs (initiated by a specialist) ▶BY MOUTH ▶Adult: 300/245 mg once daily DOSE EQUIVALENCE AND CONVERSION ▶Dose expressed as x/y mg lamivudine/tenofovir disoproxil.

PDF page 712

Cautions

Elderly (no information available)

PDF page 712

Allergy And Cross Sensitivity

Manufacturer advises contra-indicated in patients with hypersensitivity to peanut or soya products.

PDF page 712

Safety

Interactions

→Appendix 1: lamivudine. tenofovir disoproxil

PDF page 712

Renal Impairment

Manufacturer advises avoid if creatinine clearance less than 50 mL/minute (consult product literature).

PDF page 712

Dose and formulations

Medicinal Forms

There can be variation in the licensing of different medicines containing the same drug. Tablet CAUTIONARY AND ADVISORY LABELS 21 EXCIPIENTS: May contain Lecithin ▶Lamivudine with tenofovir disoproxil (Non-proprietary) Tenofovir disoproxil (as Tenofovir disoproxil fumarate) 245 mg, Lamivudine 300 mg Lamivudine 300mg / Tenofovir disoproxil 245mg tablets | 30 tablet P £9.99 | 90 tablet P £29.97

PDF page 712

Clinical care

Patient And Carer Advice

Driving and skilled tasks Manufacturer advises patients should be counselled on the effects on driving and performance of skilled tasks—increased risk of dizziness.

PDF page 712

Dose text by age group

Adult

300/245 mg once daily

First-line fragment. Read the complete Indications and Dose section above.

PDF page 712

Age labels are extracted for navigation. Check the complete source section and current local guidance before clinical use.

Drug reference

Lamivudine with tenofovir disoproxil

BNF 80 (2020–2021)

Source: BNF 80 (2020–2021)
PDF pages: 712

Review source pages for extracted sections and age labels. BNF dose snippets show only their first line.

Overview

Indications And Dose

PDF page 712

Cautions

Elderly (no information available)

PDF page 712

Allergy And Cross Sensitivity

Manufacturer advises contra-indicated in patients with hypersensitivity to peanut or soya products.

PDF page 712

Safety

Interactions

→Appendix 1: lamivudine. tenofovir disoproxil

PDF page 712

Renal Impairment

Manufacturer advises avoid if creatinine clearance less than 50 mL/minute (consult product literature).

PDF page 712

Dose and formulations

Medicinal Forms

PDF page 712

Clinical care

Patient And Carer Advice

Driving and skilled tasks Manufacturer advises patients should be counselled on the effects on driving and performance of skilled tasks—increased risk of dizziness.

PDF page 712

Dose text by age group

Adult

300/245 mg once daily

First-line fragment. Read the complete Indications and Dose section above.

PDF page 712

Age labels are extracted for navigation. Check the complete source section and current local guidance before clinical use.